Rigel Pharmaceuticals, Inc. (RIGL)

1.3250 +0.1850 (+16.23%) At close: 04:00PM EST

Rigel Pharmaceuticals, Inc.

611 Gateway Blvd
Suite 900
South San Francisco, CA 94080
United States
650 624 1100
https://www.rigel.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 155

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Raul R. Rodriguez	President, CEO & Director	1.09M	N/A	1961
Mr. Dean L. Schorno CPA	Executive VP & CFO	696.67k	N/A	1963
Mr. Raymond J. Furey J.D.	Executive VP, General Counsel & Corporate Secretary	593.46k	N/A	1968
Mr. David A. Santos	Executive VP & Chief Commercial Officer	681.63k	N/A	1963
Mr. Joseph Lasaga	Executive Vice President of Corporate Development	N/A	N/A	1975
Ms. Julie Patel	Senior VP of Human Resources	N/A	N/A	N/A
Dr. Esteban S. Masuda	Executive Vice President of Research	537.21k	N/A	1962
Mr. Tarek Sallam	Vice President of Marketing	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Corporate Governance

Rigel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 1, 2023 is 4. The pillar scores are Audit: 7; Board: 4; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.